US biotech major Amgen (Nasdaq: AMGN) has announced that its trial on whether the cholesterol-lowering drug Repatha (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) has met its primary composite endpoint.
This endpoint measured the time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, comparing Repatha in combination with statin therapy to placebo plus statin therapy.
The key secondary endpoint in the Fourier trial was also met, measuring the time to cardiovascular death, myocardial infarction or stroke.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze